MedTrace Logo

Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults

NCT05835479 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-04-03

No results posted yet for this study

Summary

This study aims to generate clinical data on the efficacy, safety, and tolerability of rezafungin combined with 7 days of co-trimoxazole for treatment of Pneumocystis pneumonia (PCP) in adults living with human immunodeficiency virus (HIV), which would expand the knowledge of clinical use of rezafungin.

Conditions

  • Pneumocystis Pneumonia

Interventions

DRUG

Co-Trimoxazole

Oral co-trimoxazole or Intravenous (IV) co-trimoxazole for infusion. Anti fungal medication

DRUG

Rezafungin Acetate / Co Trimoxazole

Rezafungin for infusion. Intravenous anti fungal therapy Oral co-trimoxazole or Intravenous (IV) co-trimoxazole for infusion. Anti fungal medication

Sponsors & Collaborators

  • Mundipharma Research Limited

    lead INDUSTRY

Principal Investigators

  • Mohit Joshi, MD · Mundipharma Research Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-14
Primary Completion
2025-05-31
Completion
2025-08-31

Countries

  • South Africa

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05835479 on ClinicalTrials.gov